Webinar Date/Time: Thursday, May 2nd, 2024 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
Join us for “The Biotech Reset: Navigating the Path Forward”, an insightful webinar where experts from IQVIA Biotech, IQVIA Institute and IQVIA explore the dynamic reset within the biotech market. Our experts will guide you through this compelling journey, where scientific ambition intertwines with the ever-evolving landscape of clinical research, leveraging strategic partnerships to achieve remarkable outcomes. Don’t miss out on key discussions covering regulatory/strategic drug development, novel trial design and the rise of AI in clinical research!
Register Free:
https://www.appliedclinicaltrialsonline.com/act/biotech-reset
Event overview
Join us in this insightful webinar as we delve into the dynamic reset seen within the biotech market, exploring the renewed optimism and trends impacting biotech companies and the strategic path to drug development. This discussion illuminates the industry’s transition from adapting in uncertainty to growth within a vibrant era of innovation, with a focus on optimizing R&D spend to quickly deliver robust scientific evidence. Our experts will guide you through this compelling journey where scientific ambition intertwines with the ever-evolving landscape of clinical research, and the importance of leveraging strategic partnerships to achieve remarkable outcomes.
During this webinar you will:
Explore regulatory challenges and opportunities with Project Optimus, diversity plans and data privacy.
Speakers:
Meg Hooton
President
IQVIA Biotech
Megan Hooton, President of IQVIA Biotech, leads the strategic direction of global business, ensuring successful project delivery across all Biotech and MedTech clinical trials. With over three decades of experience in managing global research and development, Meg provides oversight to clinical teams, investigator site services, data services and therapeutic divisions. Her remarkable journey—from nursing to biotech leadership—reflects not only her wealth of operational insights but also her cross-cultural expertise and unwavering commitment to advancing healthcare.
Murray Aitken
Executive Director
IQVIA Institute for Human Data Science
Murray Aitken, Executive Director of the IQVIA Institute for Human Data Science, is a globally recognized authority in addressing challenges within the healthcare industry. With a rich 15-year history at IQVIA, he has seamlessly navigated diverse roles spanning healthcare insights, corporate strategy and consulting. Previously, he was a partner at McKinsey & Company in the US and South Korea, for which he focused heavily on Life Sciences. Murray earned his MBA from Harvard and a Masters of Commerce from the University of Auckland. He is a sought-after speaker at international healthcare forums. His insightful perspectives grace esteemed publications including The Wall Street Journal, The Financial Times, Fortune and CNBC.
Keith McDonald
Head of Drug Development Strategy, Regulatory Affairs & Drug Development Solutions
IQVIA
Keith McDonald, a seasoned expert with over 25 years in regulatory affairs and drug development, leads as the Head of Drug Development Strategy at IQVIA. His extensive regulatory authority expertise in clinical trials, marketing authorization approvals and policy development makes him an expert in our industry. His many contributions include providing regulatory authority scientific advice to leading the UK Covid Therapeutics Taskforce, where he shaped policy and secures marketing authorizations.
Register Free:
https://www.appliedclinicaltrialsonline.com/act/biotech-reset
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Effect of AI/ML, Real World Evidence and Master Protocols on Trial Success
July 7th 2025How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical oversight and increased collaboration, are contributing to better healthcare delivery and strengthening the role of clinical research in driving global health progress.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Effect of AI/ML, Real World Evidence and Master Protocols on Trial Success
July 7th 2025How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical oversight and increased collaboration, are contributing to better healthcare delivery and strengthening the role of clinical research in driving global health progress.
2 Commerce Drive
Cranbury, NJ 08512